*For Researchers* Fund Sophia, managed by the King Baudouin Foundation, has launched a call for research projects on Multiple System Atrophy (MSA) and related diseases characterized by Parkinsonism but excluding idiopathic Parkinson. They are offering € 150.000 to support a research project over a period of 2 years. Deadline for application: 12/01/2022 See here for more information Sophia (Fund) | Koning Boudewijnstichting (kbs-frb.be)

News: Whole genome sequencing helps to unravel mystery of rare disease diagnosis | NIHR

Alterity Therapeutics announce ‘Clinical trial to enroll patients with early-stage Multiple Systems Atrophy’, more information in the announcement here

EmeraMed builds momentum in rare disease. EmeraMed’s emeramide saw its PTSR in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) rise by nine points each after a Phase II trial was completed. The PTSR in PSP currently sits at 27% while that in MSA is now 56%. PSP and MSA are both atypical forms of Parkinson’s disease. The Phase II placebo-controlled crossover study (NCT04184063) evaluating the drug’s effect on symptoms and health-related quality of life over 28 days enrolled 20 patients with PSP or MSA. Emermaide, also known as NBMI, is an oral isophthalamide derivative that can prevent oxidative damage and reduce disease toxicity. The study completion, which was posted to ClinicalTrials.gov on 23 September, resulted in a modest one-point bump to the drug’s LoA in MSA to 2%, but there was no LoA change in PSP, which remained at 1%. EmeraMed is headquartered in Ireland and also operates in the US and Sweden. Read more about the trial on the ClinicalTrials.gov website

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 (prnewswire.com) See the conference poster here

Results of M-Star trial announced. We have been disappointed to learn from Biohaven that one of the possible treatment drugs, Verdiperstat, for MSA has not given the results hoped for in the phase three trial undertaken over the past year. Our Biohaven colleagues have said ‘Thank you so much for all your incredible effort and hard work on this trial. We could not have done this without your support – from helping with recruitment to connecting us with people with MSA and their families to understand their experience better. We are hoping that this global MSA study (the largest ever conducted) will help further the research for this rare degenerative disease. ‘ Read the full press release here. https://www.prnewswire.com/news-releases/biohaven-provides-update-on-phase-3-trial-and-multiple-system-atrophy-msa-program-301385193.html?tc=eml_cleartime

Here is a podcast by Dr Camille Carroll Associate Professor and Honorary Consultant Neurologist Peninsula Medical School (Faculty of Health), NSL for Neurology NIHR CRN, talking about The role of digital, technology, such as sensors and wearables, in clinical trials

Research project ‘Abdominal Binders to Treat Orthostatic Hypotension in Multiple System Atrophy’ receives additional funding

Alterity Therapeutics press release announces publication of data for ATH434 (a small molecule drug candidate) in a mouse model of Multiple System Atrophy

The full publication ‘ATH434 Reduces a-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy’ on the Movement Disorders Journal website

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Researchers move closer to a test that can sniff out Parkinson’s

Creating drugs to restore mitochondria and stop Parkinson’s

Parkinson’s results beyond researchers’ wildest dreams

The MSA Coalition (USA) research news and therapeutic pipeline summary

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_gtag_UA_72896010_1	1 minute	This cookie is set by Google and is used to distinguish users.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.

Cookie	Duration	Description
apbct_cookies_test	session	CleanTalk–Used to prevent spam on our comments and forms and acts as a complete anti-spam solution and firewall for this site.
apbct_page_hits	session	CleanTalk–Used to prevent spam on our comments and forms and acts as a complete anti-spam solution and firewall for this site.
apbct_site_landing_ts	session	CleanTalk–Used to prevent spam on our comments and forms and acts as a complete anti-spam solution and firewall for this site.
apbct_timestamp	session	CleanTalk–Used to prevent spam on our comments and forms and acts as a complete anti-spam solution and firewall for this site.
cookielawinfo-checkbox-functional	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
m	2 years	No description available.
spbc_secfw_ip_wl	1 month	No description
wordpress_apbct_antibot	session	No description